Metastatic castration resistant prostate cancer patients' experience with Radium-223 treatment in Japan.

IF 3 4区医学 Q2 ONCOLOGY Future oncology Pub Date : 2024-04-01 Epub Date: 2024-01-26 DOI:10.2217/fon-2023-0870

Koichiro Akakura, Hiroji Uemura, Satoru Kawakami, Akira Yokomizo, Motonobu Nakamura, Kazuo Nishimura, Tetsushi Komori, Dianne Athene Ledesma

{"title":"Metastatic castration resistant prostate cancer patients' experience with Radium-223 treatment in Japan.","authors":"Koichiro Akakura, Hiroji Uemura, Satoru Kawakami, Akira Yokomizo, Motonobu Nakamura, Kazuo Nishimura, Tetsushi Komori, Dianne Athene Ledesma","doi":"10.2217/fon-2023-0870","DOIUrl":null,"url":null,"abstract":"Aim: We aimed to determine Japanese metastatic castration resistant prostate cancer (CRPC) patients' Ra-223 treatment experience. Patients & methods: Patients answered the Cancer Therapy Satisfaction Questionnaire (CTSQ domains: Satisfaction with Therapy [SWT], Expectations of Therapy [ET], Feelings about Side Effects [FSE]), the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) and the FACT-Bone Pain (FACT-BP) Questionnaire at baseline, during (vists 3 and 5) and after treatment (end of observation; EOO). Results: Data from 72 patients were included. Baseline median CTSQ scores SWT: 66.1 (IQR19.7), ET: 75.0 (IQR45), and FSE 68.8 (IQR 34.4) were unchanged during vists 3 and 5, but the SWT (-3.57 [IQR17.9]) and ET (-5.0 [IQR30]) decreased while FSE was unchanged (0.0 [IQR31.25]) at EOO. The median MAX-PC (18.0 [IQR 49]) score was unchanged (0.0, IQR 6) while the median FACT BP (54.0 [IQR13]) score decreased by -1.0 (IQR 8) at EOO. Conclusion: Japanese metastatic castration resistant prostate cancer patients' experience is stable during Ra-223 treatment.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"781-798"},"PeriodicalIF":3.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/fon-2023-0870","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: We aimed to determine Japanese metastatic castration resistant prostate cancer (CRPC) patients' Ra-223 treatment experience. Patients & methods: Patients answered the Cancer Therapy Satisfaction Questionnaire (CTSQ domains: Satisfaction with Therapy [SWT], Expectations of Therapy [ET], Feelings about Side Effects [FSE]), the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) and the FACT-Bone Pain (FACT-BP) Questionnaire at baseline, during (vists 3 and 5) and after treatment (end of observation; EOO). Results: Data from 72 patients were included. Baseline median CTSQ scores SWT: 66.1 (IQR19.7), ET: 75.0 (IQR45), and FSE 68.8 (IQR 34.4) were unchanged during vists 3 and 5, but the SWT (-3.57 [IQR17.9]) and ET (-5.0 [IQR30]) decreased while FSE was unchanged (0.0 [IQR31.25]) at EOO. The median MAX-PC (18.0 [IQR 49]) score was unchanged (0.0, IQR 6) while the median FACT BP (54.0 [IQR13]) score decreased by -1.0 (IQR 8) at EOO. Conclusion: Japanese metastatic castration resistant prostate cancer patients' experience is stable during Ra-223 treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

日本转移性抗性前列腺癌患者接受镭-223 治疗的经验。

目的：我们旨在了解日本转移性去势抵抗性前列腺癌 (CRPC) 患者的 Ra-223 治疗经历。患者与方法患者回答癌症治疗满意度问卷（CTSQ）：对治疗的满意度 [SWT]、对治疗的期望 [ET]、对副作用的感受 [FSE]）、前列腺癌焦虑量表 (MAX-PC) 和 FACT 骨痛 (FACT-BP) 问卷。结果：共纳入 72 名患者的数据。基线中位 CTSQ 分数 SWT：66.1 (IQR19.7)、ET：75.0 (IQR45) 和 FSE：68.8 (IQR34.4) 在第 3 次和第 5 次就诊时保持不变，但在 EOO 就诊时，SWT（-3.57 [IQR17.9]）和 ET（-5.0 [IQR30]）有所下降，而 FSE 则保持不变（0.0 [IQR31.25]）。在 EOO 时，MAX-PC（18.0 [IQR 49]）的中位数评分保持不变（0.0，IQR 6），而 FACT BP（54.0 [IQR 13]）的中位数评分下降了-1.0（IQR 8）。结论日本转移性阉割抵抗性前列腺癌患者在 Ra-223 治疗期间的体验是稳定的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.